JPWO2021151889A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021151889A5 JPWO2021151889A5 JP2022545136A JP2022545136A JPWO2021151889A5 JP WO2021151889 A5 JPWO2021151889 A5 JP WO2021151889A5 JP 2022545136 A JP2022545136 A JP 2022545136A JP 2022545136 A JP2022545136 A JP 2022545136A JP WO2021151889 A5 JPWO2021151889 A5 JP WO2021151889A5
- Authority
- JP
- Japan
- Prior art keywords
- renal
- acid sequence
- antigen
- amino acid
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966258P | 2020-01-27 | 2020-01-27 | |
| US62/966,258 | 2020-01-27 | ||
| PCT/EP2021/051753 WO2021151889A1 (en) | 2020-01-27 | 2021-01-26 | ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023511686A JP2023511686A (ja) | 2023-03-22 |
| JP2023511686A5 JP2023511686A5 (https=) | 2024-01-23 |
| JPWO2021151889A5 true JPWO2021151889A5 (https=) | 2024-01-23 |
| JP7706458B2 JP7706458B2 (ja) | 2025-07-11 |
Family
ID=74561850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545136A Active JP7706458B2 (ja) | 2020-01-27 | 2021-01-26 | 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230112035A1 (https=) |
| EP (1) | EP4096785A1 (https=) |
| JP (1) | JP7706458B2 (https=) |
| KR (1) | KR20220132567A (https=) |
| CN (1) | CN115151305A (https=) |
| AR (1) | AR121193A1 (https=) |
| AU (1) | AU2021213403B2 (https=) |
| BR (1) | BR112022014633A2 (https=) |
| CA (1) | CA3167390A1 (https=) |
| CL (1) | CL2022001999A1 (https=) |
| CO (1) | CO2022011661A2 (https=) |
| CR (1) | CR20220392A (https=) |
| EC (1) | ECSP22066085A (https=) |
| IL (1) | IL294814A (https=) |
| MX (1) | MX2022009165A (https=) |
| PH (1) | PH12022551863A1 (https=) |
| TW (1) | TWI854088B (https=) |
| WO (1) | WO2021151889A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11359024B2 (en) | 2018-09-07 | 2022-06-14 | Pfizer Inc. | Anti-AVB8 antibodies and compositions and uses thereof |
| US20260035468A1 (en) | 2022-09-12 | 2026-02-05 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
| TW202446789A (zh) * | 2023-03-31 | 2024-12-01 | 美商建南德克公司 | 抗αｖβ８整合素抗體及使用方法 |
| CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
| CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| MX342270B (es) * | 2010-02-18 | 2016-09-21 | The Regents Of The Univ Of California * | ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8. |
| SG2014014237A (en) * | 2011-08-17 | 2014-07-30 | Univ California | Antibodies that bind integrin alpha-v beta-8 |
| US20170073406A1 (en) * | 2014-05-06 | 2017-03-16 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| PT3157561T (pt) | 2014-06-17 | 2020-03-25 | Univ California | Anticorpos contra alfa-v beta-8 melhorados |
| EP3634485A4 (en) * | 2017-06-07 | 2021-07-21 | Silverback Therapeutics, Inc. | CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES |
| CA3112523A1 (en) * | 2018-08-08 | 2020-02-13 | The General Hospital Corporation | Integrin antagonists |
-
2021
- 2021-01-13 TW TW110101209A patent/TWI854088B/zh active
- 2021-01-26 US US17/759,388 patent/US20230112035A1/en active Pending
- 2021-01-26 BR BR112022014633A patent/BR112022014633A2/pt unknown
- 2021-01-26 KR KR1020227028722A patent/KR20220132567A/ko active Pending
- 2021-01-26 JP JP2022545136A patent/JP7706458B2/ja active Active
- 2021-01-26 WO PCT/EP2021/051753 patent/WO2021151889A1/en not_active Ceased
- 2021-01-26 CR CR20220392A patent/CR20220392A/es unknown
- 2021-01-26 CA CA3167390A patent/CA3167390A1/en active Pending
- 2021-01-26 AU AU2021213403A patent/AU2021213403B2/en active Active
- 2021-01-26 IL IL294814A patent/IL294814A/en unknown
- 2021-01-26 CN CN202180010557.1A patent/CN115151305A/zh active Pending
- 2021-01-26 PH PH1/2022/551863A patent/PH12022551863A1/en unknown
- 2021-01-26 EP EP21703839.7A patent/EP4096785A1/en active Pending
- 2021-01-26 MX MX2022009165A patent/MX2022009165A/es unknown
- 2021-01-27 AR ARP210100199A patent/AR121193A1/es unknown
-
2022
- 2022-07-25 CL CL2022001999A patent/CL2022001999A1/es unknown
- 2022-08-18 CO CONC2022/0011661A patent/CO2022011661A2/es unknown
- 2022-08-23 EC ECSENADI202266085A patent/ECSP22066085A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3093026B1 (en) | Scfv antibodies which pass epithelial and/or endothelial layers | |
| JP2011207882A5 (https=) | ||
| RU2746812C1 (ru) | Способы и композиции для лечения амилоидозов | |
| CA2583910A1 (en) | Angiopoietin-2 specific binding agents | |
| CN113874073A (zh) | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 | |
| JP2019511911A5 (https=) | ||
| JP2019504064A5 (https=) | ||
| TW201422239A (zh) | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 | |
| JP2015503909A5 (https=) | ||
| JP2022515480A (ja) | 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体 | |
| JP2017507131A5 (https=) | ||
| US12098207B2 (en) | Anti-IL-36R antibodies for the treatment of pyoderma gangrenosum | |
| JP2022547452A (ja) | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 | |
| JP2022502024A5 (https=) | ||
| JPWO2021151889A5 (https=) | ||
| JP2017530089A (ja) | 抗ｉｌ４−ｉｌ１３二重特異性抗体 | |
| WO2023020624A1 (en) | Use of alpha-enolase antagonist in treating fibrotic diseases | |
| JP2018531625A5 (https=) | ||
| JP2018533588A (ja) | 治療パラダイム | |
| Ashfaque et al. | Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody | |
| US20230049147A1 (en) | Anti-il-36r antibodies for the treatment of a fibrotic condition | |
| JPWO2019195273A5 (https=) | ||
| WO2022234440A1 (en) | Treatment for lupus nephritis using anti-baffr antibodies | |
| CN118591386A (zh) | 抗突变体钙网蛋白(calr)抗体及其用途 | |
| Jeyabalan et al. | Paraneoplastic focal segmental glomerulosclerosis associated with acute lymphocytic leukemia |